Regeneron Pharmaceuticals REGN Regeneron's share of profits — Revenue

Other product segments

Similar metrics at other companies

INCYProduct royalty revenues — Total revenues

$151.19M+15.7%

AQSTRoyalty — Revenue

$0—

ANIPBrand royalties and other revenues — Net Revenues

$21.54M—

GERNRoyalties — Total revenues

$66K-60.5%

AQSTProprietary product revenue, net — Revenue

$0-100%

ABUSRevenue from collaborations and licenses — Revenue

$178.74M+21,912%

Questions, answered.

What is Regeneron Pharmaceuticals's regeneron's share of profits — revenue?

Regeneron Pharmaceuticals (REGN) reported regeneron's share of profits — revenue of $1.45B in Q1 2026.

How has Regeneron Pharmaceuticals's regeneron's share of profits — revenue changed year-over-year?

Regeneron Pharmaceuticals's regeneron's share of profits — revenue increased by 42.5% year-over-year, from $1.02B to $1.45B.

What is the long-term trend for Regeneron Pharmaceuticals's regeneron's share of profits — revenue?

Over 3 years (2022 to 2025), Regeneron Pharmaceuticals's regeneron's share of profits — revenue has grown at a 36.0% compound annual growth rate (CAGR), from $2.08B to $5.24B.

What does regeneron's share of profits — revenue mean?

This metric represents the company's recognized portion of net profits derived from collaborative arrangements and joint commercialization agreements with strategic partners. It reflects the economic benefit flowing to the company from products developed and marketed in partnership, rather than through wholly-owned sales channels. This figure is critical for assessing the profitability of the company's R&D-heavy business model and its reliance on external collaboration revenue streams.